Meet the ARC Team at World CDx Boston
5–8 October 2026 | Boston, MA
Visit ARC at booth 33
Hear from James Lappin: Thursday 8 October, 11:00–11:30 a.m.
Will you be attending World CDx Boston this October?
Meet Seamus, David, Lindsey, Andrew and James to discuss how ARC’s specialist Dx CRO, Laboratory and Pharma Tech services can support your IVD/CDx programme—from study planning and regulatory strategy through clinical trial testing, oversight and delivery.
Why meet with ARC?
ARC Laboratory has received formal confirmation from the UK MHRA that, because of our Northern Ireland location, we can self-designate to enable the testing of both EU and UK clinical trial samples under the IVDR Health Institution Exemption, Article 5(5).
For eligible studies, this removes the need for a separate IVDR Performance Study application or Competent Authority approval.
What could this mean for your studies?
- Faster study start-up
- Reduced regulatory burden
- Greater flexibility as assays evolve across EU and UK programmes
Meet the ARC team
Seamus, David, Lindsey, Andrew and James will be available throughout the event to discuss:
- Regulatory strategy and compliance
- Laboratory and clinical testing
- Pharma AI solutions - ARC360®
- IVD and IVDR requirements
- EU and UK clinical trial testing
- Companion diagnostic development
Hear from James Lappin
James Lappin
Director of Corporate Affairs
ARC Regulatory
Thursday 8 October | 11:00–11:30 a.m.
Rethinking the Pharma–Diagnostic Partnership
How specialist oversight can reduce complexity, manage risk and optimise the clinical trial lifecycle
James will explore how specialist oversight of diagnostic partners and studies can help pharma teams:
- Clarify IVD study responsibilities through clearer ownership and accountability across the clinical trial lifecycle
- Reduce handovers, gaps and duplication across diagnostic partners, vendors and workstreams
- Strengthen oversight and coordination across multiple diagnostic activities
- Reduce risk, save time and ease pressure on internal teams through a more integrated approach
